This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Management

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

If a diagnosis of Hyperkinetic Disorder or Attention Deficit/ Hyperactivity Disorder is suspected then the patient should be referred for specialist assessment (child psychiatrist or paediatrician with specialist expertise in this area) (1).

Management includes:

  • non-drug management
  • drug management

Notes (2):

  • children under 5 years of age:
    • first-line treatment is an ADHD-focused group parent-training programme to parents or carers of children under 5 years with ADHD
    • if after an ADHD-focused group parent-training programme, ADHD symptoms across settings are still causing a significant impairment in a child under 5 years after environmental modifications have been implemented and reviewed, obtain advice from a specialist ADHD service with expertise in managing ADHD in young children (ideally a tertiary service)
    • medication for ADHD should not be offered for any child under 5 years without a second specialist opinion from an ADHD service with expertise in managing ADHD in young children (ideally a tertiary service)

  • children aged 5 years and over and young people
    • appropriate informatin about ADHD should be given and offer additional support to parents and carers of all children aged 5 years and over and young people with ADHD. The support should be ADHD focused, can be group based and as few as 1 or 2 sessions
    • if a child aged 5 years or over or young person has ADHD and symptoms of oppositional defiant disorder or conduct disorder, offer parents and carers a parent-training programme as well as group-based ADHD-focused support
    • medication for children aged 5 years and over and young people should only be offered only if:
      • their ADHD symptoms are still causing a persistent significant impairment in at least one domain after environmental modifications have been implemented and reviewed
      • they and their parents and carers have discussed information about ADHD
      • a baseline assessment has been carried out
    • a course of cognitive behavioural therapy (CBT) should be considered for young people with ADHD who have benefited from medication but whose symptoms are still causing a significant impairment in at least one domain, addressing the following areas:
      • social skills with peers
      • problem-solving
      • self-control
      • active listening skills
      • dealing with and expressing feelings

  • adults with ADHD:
    • medication should be offered to adults with ADHD if their ADHD symptoms are still causing a significant impairment in at least one domain after environmental modifications have been implemented and reviewed
    • non-pharmacological treatment should be considered for adults with ADHD who have:
      • made an informed choice not to have medication
      • difficulty adhering to medication
      • found medication to be ineffective or cannot tolerate it
    • non-pharmacological treatment should be considered in combination with medication for adults with ADHD who have benefited from medication but whose symptoms are still causing a significant impairment in at least one domain
    • when non-pharmacological treatment is indicated for adults with ADHD, NICE have suggested that the following should be offered as a minimum:
      • a structured supportive psychological intervention focused on ADHD
      • regular follow-up either in person or by phone
      • treatment may involve elements of or a full course of CBT
    • drug treatment
      • lisdexamfetamine or methylphenidate are options as first-line pharmacological treatment for adults with ADHD
      • a systematic review concluded (3):
        • found no certain evidence that intermediate release (IR) methylphenidate compared with placebo or lithium can reduce symptoms of ADHD in adults (low- and very low-certainty evidence)
        • adults treated with IR methylphenidate are at increased risk of gastrointestinal and metabolic-related harms compared with placebo. Clinicians should consider whether it is appropriate to prescribe IR methylphenidate, given its limited efficacy and increased risk of harms.

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.